10 Biggest Price Target Changes For Wednesday
Goldman Sachs lowered the price target on Nucor Corporation (NYSE: NUE) from $123 to $108. Nucor shares fell 3.6% to $95.15 in pre-market trading.
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 5)
HC Wainwright & Co. Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $160
HC Wainwright & Co. analyst Douglas Tsao maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Buy and raises the price target from $135 to $160.
What 7 Analyst Ratings Have To Say About Biohaven Pharma Hldgs
Biohaven Pharma Hldgs (NYSE:BHVN) has observed the following analyst ratings within the last quarter:
Piper Sandler Maintains Overweight on Biohaven Pharma Hldgs, Raises Price Target to $156
Piper Sandler analyst Christopher Raymond maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Overweight and raises the price target from $140 to $156.
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 30)
Why Are Biohaven Shares Trading Lower On Monday?
Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) has announced results from a focused analysis of verdiperstat trial in verdiperstat in multiple system…
Biohaven Therapeutics Files For U.S. Patent Titled ‘USE OF RILUZOLE PRODRUGS TO TREAT ALZHEIMER’S DISEASE’
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=7615&p=153&f=G&l=50&d=PG01&S1=20210923.PD.&OS=PD/20210923&RS=PD/20210923
TENX: Second Quarter Results
By John Vandermosten, CFA
NASDAQ:TENX
READ THE FULL TENX RESEARCH REPORT